Mode
Text Size
Log in / Sign up
Phase 4 N=176 Randomized Treatment

Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.

Type 2 Diabetes Mellitus

Enrolled (actual)
176
Serious AEs
0.0%
Results posted
May 2011
Primary outcome: Primary: Hospital Length of Stay — 2.7; 3.1 days — p=0.58

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
insulin aspart (Drug); insulin detemir (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Rush University Medical Center
Primary completion
Jul 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Hospital Length of Stay
2.7; 3.1 0.58
SECONDARY
Average Blood Glucose During the Hospital Admission
SECONDARY
Frequency of Hypoglycemia
SECONDARY
Efficacy of Blood Glucose Lowering During the Emergency Room Stay
SECONDARY
Frequency of Hypoglycemia During Emergency Room Therapy With Insulin

Summary

This study will examine two questions: 1. Whether insulin treatment of high blood sugar in patients with diabetes while they are in the emergency room will improve how quickly they recover from illness if they need to be hospitalized. 2. Whether immediately beginning long lasting insulin detemir in patients with diabetes when they are admitted to hospital from the emergency room will improve how quickly they recover from the illness which necessitated hospitalization.

Eligibility Criteria

Inclusion Criteria

  • Age 18-80 years
  • History of type 2 diabetes mellitus for at least 3 months
  • Prior therapy with dietary management, oral agents, or insulin
  • Non child-bearing potential or a negative urine pregnancy test
  • Initial blood glucose in ER > 200 mg/dl

Exclusion Criteria

  • Subsequent finding of diabetic ketoacidosis or hyperosmolar non-ketotic syndrome after initial evaluation.
  • Patients with critical illness suspected to require intensive care unit admission or direct surgical intervention.
  • History of current drug or alcohol abuse.
  • History of current mental illness
  • Inability to give informed consent
  • Female patients who are pregnant or are breast feeding
  • Patients who have clinically significant liver disease with AST/ALT (aspartate transaminase/alanine transaminase) > 3 times the upper range of normal
  • Patients currently treated with dialysis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00591227). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search